Durect To Receive Near-Term Upfront Cash Payments Totaling $6 Million, Potential Additional Milestone Payments Of Up To $130 Million And Tiered Low To Mid Double-Digit Royalties Based On U.S. Sales- Innocoll Granted Exclusive Development And Commercialization Rights To Posimir In The United States- Durect To Discuss Agreement On Conference Call Et Durect To Receive Near-Term Upfront Cash Payments Totaling $6 Million, Potential Additional Milestone Payments Of Up To $130 Million And Tiered Low To Mid Double-Digit Royalties Based On Us Sales- Innocoll Granted Exclusive Development And Commercialization Rights To Posimir In The United States- Durect To Discuss Agreement On Conference Call Innocoll Biotherapeutics Plc Is A Global Specialty Pharmaceutical Company Headquartered In Athlone, Ireland. Innocoll Biotherapeutics Plc And Its Subsidiaries Innocoll Holdings Limited And Innocoll Pharmaceuticals Limited, Are Focused On The Development And Commercialization Of Pharmaceutical Technologies To Meet Some Of Today'S Most Important Healthcare Challenges. Innocoll Biotherapeutics Plc Is A Portfolio Business Of Gurnet Point Capital. Www.Innocoll.ComAbout PosimirPosimir
